A 34-year-old has been tired for months. Her knees ache some mornings, and her fingers feel stiff when she wakes. Her primary care clinician orders a blood test for antinuclear antibodies, known as the ANA, and it comes back positive. By Sunday night she has read about lupus on a dozen websites and decided she has it.
The result is weaker evidence than it feels. In federal survey data from 2011 and 2012, analyzed in 2020, about 1 in 6 Americans aged 12 and older, 15.9%, tested positive for these antibodies. The researchers put that at roughly 41 million people. That is more than two and a half times the number of Americans a recent health-records study found had been diagnosed with any autoimmune disease at all.
Autoimmune disease is common, nobody agrees exactly how common, and the test people ask about first is easy to misread. Here is what the counts show, what the ANA can and can’t tell you, why diagnosis takes so long, and what living on immune-suppressing medicine means for infections and vaccines.
How many Americans have autoimmune disease depends on who counts
In an autoimmune disease, the immune system makes antibodies or cells that attack the body’s own tissues. Ask how many Americans live with one, and official sources don’t agree:
- More than 23.5 million, with more than 80 known types, according to the HHS Office on Women’s Health (page updated May 2026).
- About 8% of the population, according to the NIH Office of Research on Women’s Health.
- 23.5 to 50 million, across more than 140 diseases, in NIH’s first strategic plan for autoimmune disease research, announced in September 2025.
- 7.6% to 9.4%, a 2009 estimate cited by the National Academies in 2022. That figure covered only 29 diseases, and the report noted that by some counts there are around 150.
The most detailed recent count is also the lowest. A team led by Aaron H. Abend of the Autoimmune Registry analyzed electronic health records from six academic health systems serving about 10.4 million people between 2011 and mid-2022. The study, published in The Journal of Clinical Investigation (online December 2024), found 581,343 people with at least one of 105 autoimmune diseases. Projected to the 2022 US population, that is about 15.4 million people, or 4.6%.
Why so much lower? Part of the answer is a billing quirk. Because US health records double as billing records, a clinician may enter a provisional diagnosis code simply to justify ordering a test that might rule the disease out. So the team counted a person only if the same diagnosis appeared at least twice, 30 or more days apart. Counting a single code would have inflated the numbers by 31% to 53% for the diseases they checked. The authors also argue that older estimates, built by adding up disease-by-disease studies, count some people twice. People with one autoimmune disease often have another: in their data, 34% did.
The records study has limits its authors name. Academic centers see sicker patients, coding errors creep in (type 2 diabetes is sometimes miscoded as type 1), and rare diseases without their own billing codes get missed. The five most common conditions it found were rheumatoid arthritis, psoriasis, type 1 diabetes, Graves’ disease and autoimmune thyroiditis.
So the honest answer is a range: at least 15 million Americans, and possibly more than three times that, depending on which diseases count and how they are counted. Those figures come from different methods and years. None of them proves another wrong.
Why most patients are women, and how big the gap is
Every source agrees that women are the majority. They disagree on the size. NIH’s women’s health office says nearly 80% of people with autoimmune disease are women. In the health-records study, women made up 63%, a ratio of about 1.7 to 1. That study found autoimmune disease in 5.8% of US females and 3.5% of males, and 17 of its 20 most common diseases were more frequent in women. The Office on Women’s Health notes that these diseases often begin in the childbearing years.
The gap doesn’t mean men get off lightly. NIH’s 2025 plan says men often have a more severe course and face a higher risk of death.
Why the sex difference exists is still open. One candidate explanation came from a 2024 study. A Stanford team, publishing in Cell, studied Xist, a molecule made only in female cells that switches off one of the two X chromosomes. Male mice engineered to make it produced autoantibodies, and in a lupus model they developed worse disease than ordinary males. Human patients with autoimmune diseases also carried antibodies against parts of the XIST complex.
That is a plausible mechanism, shown mostly in mice. It is not proof of why women develop these diseases, and hormones, other genes and environmental exposures all remain under study.
The ANA test rules lupus out far better than it rules it in
An ANA test looks for antibodies that react with material inside the nucleus of a cell. In the standard method, a lab spreads diluted blood over a layer of cells and checks under a fluorescent microscope whether antibodies stick. The result is reported as a titer, the most diluted sample that still lights up. A titer of 1:160 means antibodies were still visible after the blood was diluted 160 times, which signals more antibody than 1:40.
Where a lab draws its cutoff changes the picture. In a 1997 study run by 15 international laboratories, people presumed healthy, aged 20 to 60, tested positive 31.7% of the time at 1:40 and 13.3% at 1:80. Only 5% were positive at 1:160, and 3.3% at 1:320. A low cutoff catches nearly everyone with lupus, scleroderma or Sjögren’s syndrome, and it flags a large share of healthy people too.
MedlinePlus, from the National Library of Medicine, says an ANA result alone cannot diagnose a specific disease. Healthy people can carry these antibodies, levels tend to climb with age, and positive results are especially common in women over 65. Certain medicines can trigger them, and a viral infection can produce a short-lived positive. A negative result makes an autoimmune disorder less likely, the page adds, but doesn’t completely exclude one.
Lupus shows why the test is lopsided. Under 2019 classification criteria from the European League Against Rheumatism and the American College of Rheumatology (ACR), a positive ANA at least once is the entry ticket. Without it, a person can’t be classified as having lupus. With it, they still need enough weighted points from findings in the skin, joints, kidneys, blood or nervous system, or from more specific antibodies. In the validation group, the criteria identified 96.1% of people with lupus and correctly excluded 93.4% of those without it. They were designed to select patients for research, though, not to diagnose one person in an exam room.
Positive results have also become more common. The 15.9% figure from 2011 and 2012 was up from 11.0% in the same survey’s 1988 to 1991 round, when roughly 22 million people carried the antibodies. The rise was steepest among teenagers and wasn’t explained by changes in weight, smoking or drinking. Whether autoimmune disease itself is rising is a separate, unanswered question, as the records-study authors point out.
Who advises against the test, and for whom
The best-known advice is easy to credit to the wrong group. The American College of Physicians (ACP) addressed the ANA in a paper on high-value testing, and the ACR quoted it in its 2013 Choosing Wisely list: “Do not screen for ANAs in patients with non-specific symptoms, such as fatigue or myalgia, or in patients with fibromyalgia“. Myalgia means muscle aches. The logic is about odds: when disease is unlikely before the test, a positive result is more likely to be false than true.
The ACR’s own first item, graded as a strong recommendation on low-quality evidence, is narrower. It targets the follow-on tests, panels of more specific antibodies such as anti-dsDNA, Sm, RNP, SSA and SSB that some labs run automatically. The ACR advises against ordering them without both a positive ANA and real clinical suspicion of an immune disease, because they are usually negative when the ANA is negative. It names exceptions, including one antibody tied to a form of muscle inflammation. The paper calls the value of broad rheumatology panels unproven and warns that undirected testing breeds false positives, more tests and patient worry.
The correction runs in two directions. A positive ANA in someone with vague tiredness rarely settles anything. But rheumatologists don’t call the test useless: it answers a question well when there is a specific question to ask.
Why diagnosis can take years, and why the wait matters
NIH’s 2025 plan says half of patients experience significant delays in diagnosis. Lupus shows why. The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) says no single test can confirm it, its symptoms come and go, and they can resemble those of other conditions. It most often begins between ages 15 and 45, and it is more common in African American, American Indian and Asian people than in white people.
The wait carries a cost. In a 2021 study of 585 people with lupus in Germany, the average time from first symptoms to diagnosis was 47 months, nearly four years. People with longer delays reported higher disease activity, more organ damage, more fatigue and worse quality of life, after accounting for age, sex and how long they had been ill. It was a self-reported snapshot, so it shows an association rather than proof that delay caused the damage. Both things hold at once: these diagnoses are genuinely hard, and taking longer is linked to worse outcomes.
The Office on Women’s Health suggests habits that can shorten the gap: a running record of every symptom, even ones that seem unrelated; a family health history that reaches beyond parents and siblings; a specialist experienced with whichever symptom troubles you most; and further opinions if needed. NIAMS adds a detail people skip: mention symptoms you no longer have. A rash that came and went last summer is part of the pattern. How joint patterns and inflammation markers shape the early workup is covered in our piece on inflammatory pain.
Living on immune-suppressing medicine: infections and vaccines
Many autoimmune diseases are treated with drugs that quiet the immune system: steroids such as prednisone, methotrexate, and biologic drugs that block specific immune signals or remove certain immune cells. The trade-off is infection. The ACR’s 2022 vaccination guideline, published in January 2023, says both these diseases and their treatments raise the risk of vaccine-preventable infections and their complications.
Among its few strong recommendations, two named specific vaccines for people taking immunosuppressive medicines: pneumococcal vaccine for those under 65, and the recombinant shingles vaccine, which contains no live virus, for adults over 18. Most of its other recommendations are conditional, meaning the panel was unsure of the balance, and rest on low-quality evidence. It does not cover COVID-19 vaccines, and it describes itself as a complement to the recommendations of the federal vaccine advisory committee and the American Academy of Pediatrics, not a replacement.
Live vaccines are the real caution
The Centers for Disease Control and Prevention (CDC), in its immunization best-practice guidance, says people with most forms of weakened immunity should not receive live vaccines, which contain a weakened but living virus or bacterium, though it describes exceptions. The ACR guideline also conditionally advises against live vaccines for patients on immunosuppressive medication, and notes that some live vaccines, such as those for flu, typhoid and polio, have inactivated alternatives. CDC adds that all non-live vaccines can be given safely to people with weakened immunity, though they may work less well.
Two groups are easy to overlook:
- Household members. CDC says close contacts should receive all vaccines appropriate for their age and exposures, except smallpox vaccine.
- Babies exposed before birth. Some biologic drugs cross the placenta. The ACR guideline addresses rotavirus vaccine timing for infants exposed to two kinds of biologics in the second or third trimester, and says the issue should be raised with the pregnant patient before delivery so the pediatrician is prepared.
The guideline also tackles timing: steroid levels, drugs whose effects linger for months, and whether one widely used medicine should pause briefly after a flu shot. Its panel stresses that each choice depends on disease activity and the risk of a flare. Whether anything changes around a vaccine is a decision for the prescribing rheumatologist or specialist, ideally made well before the appointment.
Do vaccines trigger flares?
This fear stops many people. The ACR panel weighed it and reported that “the vast majority of studies failed to show any increased rate of flare after influenza vaccination”. Results were similar for other vaccines, though that evidence was low quality. One retrospective study found mild flares in some patients around the time of recombinant shingles vaccination, and reactions to that vaccine are common.
In this library’s terms, the claim that flu vaccine sets off flares has been tested and largely not supported, though most of this guideline’s recommendations rest on low-quality evidence. Patients on the panel voiced strong concern anyway, which is why the guideline leans on shared decision-making rather than blanket rules. The trade-off it describes is a small, uncertain flare risk weighed against a clearer increase in infection risk.
Questions to bring when an autoimmune test comes back positive
These questions turn an alarming result into a plan. The first six fit a new positive test; the last is for people already in treatment.
- What was the titer and the pattern, and where does this lab set its cutoff? A result of 1:80 and one of 1:640 are not the same finding.
- What prompted the test? If no specific sign pointed toward an immune disease, a positive result is more likely to be a bystander.
- Which disease is on the table, and what would confirm or argue against it? In lupus, the ANA only opens the door; the points come from findings elsewhere in the body.
- Could a medicine I take, or a recent infection, explain it? Bring the complete list.
- If more antibody tests are planned, why these ones? A short, targeted list fits the ACR’s advice better than a broad panel.
- If nothing else turns up, what happens next? Watching and retesting, a referral, or a date to revisit, plus which new symptoms should bring you back sooner.
- If you take immune-suppressing treatment: before any vaccine, international trip, planned pregnancy or surgery, who decides the timing, and how much notice do they need?
Supplements marketed for autoimmune conditions, vitamin D and eating patterns are weighed in other library entries; none of them changes what a blood test can or can’t show.
When to get medical help promptly
- Possible flare signs in someone already diagnosed. NIAMS describes warning signs that include fever, a new rash, swollen or aching joints, headaches, stomach pain and more tiredness than usual. The Office on Women’s Health treats a suspected flare as a reason to phone the doctor, not to wait for the next visit.
- Fever or other signs of infection while taking immune-suppressing drugs. The ACR guideline notes that these drugs raise the risk of infections and their complications. That warrants a same-day call to the prescribing team, and whether any medicine should be paused is their decision.
- Symptoms that arrive together. Joint swelling, rashes and unexplained fevers that come and go as a group deserve an appointment and a written log.
- Emergencies. Chest pain, sudden weakness on one side of the body or severe trouble breathing call for 911, whatever the diagnosis.
The Takeaway
A positive ANA is a reason for questions, not a diagnosis. About 1 in 6 Americans aged 12 and older carried these antibodies in federal survey data from 2011 and 2012, and a negative result does far more to rule lupus out than a positive one does to rule it in.
If you already live with an autoimmune disease and take drugs that suppress the immune system, the step that pays off is settling vaccine timing with the prescribing specialist well before any appointment. Live vaccines are the genuine hazard for this group, and for flu shots, at least, the feared flares have mostly failed to appear in the studies.
Sources
- The Journal of Clinical Investigation. “Abend AH, He I, Bahroos N, et al. "Estimation of prevalence of autoimmune diseases in the United States using electronic health record data." J Clin Invest, 2025;135(4):e178722 (published online December 12, 2024). PubMed. DOI: 10.1172/JCI178722.” pubmed.ncbi.nlm.nih.gov
- Arthritis & Rheumatology. “Dinse GE, Parks CG, Weinberg CR, et al. "Increasing Prevalence of Antinuclear Antibodies in the United States." Arthritis Rheumatol, 2020;72(6):1026-1035. PubMed. DOI: 10.1002/art.41214.” pubmed.ncbi.nlm.nih.gov
- Arthritis & Rheumatism. “Tan EM, Feltkamp TE, Smolen JS, et al. "Range of antinuclear antibodies in 'healthy' individuals." Arthritis Rheum, 1997;40(9):1601-11. PubMed. DOI: 10.1002/art.1780400909.” pubmed.ncbi.nlm.nih.gov
- American College of Rheumatology (Arthritis Care & Research). “Yazdany J, Schmajuk G, Robbins M, et al. "Choosing wisely: the American College of Rheumatology's Top 5 list of things physicians and patients should question." Arthritis Care Res (Hoboken), 2013;65(3):329-39. PubMed. DOI: 10.1002/acr.21930.” pubmed.ncbi.nlm.nih.gov
- European League Against Rheumatism / American College of Rheumatology (Arthritis & Rheumatology). “Aringer M, Costenbader K, Daikh D, et al. "2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus." Arthritis Rheumatol, 2019;71(9):1400-1412. PubMed. DOI: 10.1002/art.40930.” pubmed.ncbi.nlm.nih.gov
- Lupus. “Kernder A, Richter JG, Fischer-Betz R, et al. "Delayed diagnosis adversely affects outcome in systemic lupus erythematosus: Cross sectional analysis of the LuLa cohort." Lupus, 2021;30(3):431-438. PubMed. DOI: 10.1177/0961203320983445.” pubmed.ncbi.nlm.nih.gov
- American College of Rheumatology (Arthritis Care & Research). “Bass AR, Chakravarty E, Akl EA, et al. "2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal Diseases." Arthritis Care Res (Hoboken), 2023;75(3):449-464 (published online January 4, 2023). PubMed. DOI: 10.1002/acr.25045.” pubmed.ncbi.nlm.nih.gov
- Cell. “Dou DR, Zhao Y, Belk JA, et al. "Xist ribonucleoproteins promote female sex-biased autoimmunity." Cell, 2024;187(3):733-749.e16. PubMed. DOI: 10.1016/j.cell.2023.12.037.” pubmed.ncbi.nlm.nih.gov
- Office on Women's Health, US Department of Health and Human Services. “Autoimmune diseases (page last updated May 4, 2026).” womenshealth.gov
- NIH Office of Research on Women's Health. “About the Office of Autoimmune Disease Research (OADR-ORWH).” orwh.od.nih.gov
- NIH Office of Research on Women's Health. “NIH Unveils Inaugural NIH-Wide Strategic Plan for Autoimmune Disease Research (posted September 9, 2025).” orwh.od.nih.gov
- National Academies of Sciences, Engineering, and Medicine. “Enhancing NIH Research on Autoimmune Disease (2022).” nationalacademies.org
- MedlinePlus, National Library of Medicine. “ANA (Antinuclear Antibody) Test (last updated March 19, 2025).” medlineplus.gov
- National Institute of Arthritis and Musculoskeletal and Skin Diseases. “Systemic Lupus Erythematosus (Lupus).” niams.nih.gov
- Centers for Disease Control and Prevention. “Altered Immunocompetence: General Best Practice Guidelines for Immunization (updated June 26, 2024).” cdc.gov